Commercialization Diligence Obligations. AstraZeneca shall use Commercially Reasonable Efforts to Commercialize Collaboration Products in the Field in the Territory. AstraZeneca shall use Commercially Reasonable Efforts to identify and procure the Commercialization of any Diagnostic Product reasonably necessary to Commercialize the Collaboration Products in the Territory. Upon the grant of a Regulatory Approval for a Collaboration Product in a country, AstraZeneca shall use Commercially Reasonable Efforts to market Collaboration Products in such country. AstraZeneca shall not, and shall ensure that its Affiliates and Sublicensees do not, seek Regulatory Approval for or Commercialize a Combination Collaboration Product in any country or territory prior to obtaining Regulatory Approval for and Commercializing in such country a Collaboration Product that is not a Combination Collaboration Product.
Commercialization Diligence Obligations. Following receipt by or on behalf of Xxxxxxx of Regulatory Approval for a Product in the United States or a Major European Country, Xxxxxxx will use CRE to [***]. Xxxxxxx will have no other diligence obligations under this Agreement with respect to the Commercialization of any Products. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
Commercialization Diligence Obligations. Following receipt by or on behalf of Biogen of Regulatory Approval for a Product in the United States or a Major European Market, Biogen will use Commercially Reasonable Efforts to Commercialize such Product in the United States or such Major European Market (as applicable). Biogen will have no other diligence obligations under this Agreement with respect to the Commercialization of any Products.
Commercialization Diligence Obligations. Sanofi will use Commercially Reasonable Efforts to Commercialize in the U.S. and at least three (3) Major European Countries one (1) Product in one Indication in the Field for which it receives Regulatory Approval.
Commercialization Diligence Obligations. Licensee will use [**] to Commercialize [**] Licensed Product for use in the Field in [**].
Commercialization Diligence Obligations. On an Option Program-by-Option Program basis, Biogen will use Commercially Reasonable Efforts to [***].
Commercialization Diligence Obligations. Takeda will use Commercially Reasonable Efforts to perform the Co-Funded Commercialization Activities under the Co-Funded [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Commercialization Plan and to otherwise Commercialize each Product in each Major Market in which such Product receives Marketing Approval. Takeda will have no other diligence obligations under this Agreement to Commercialize any Products, and Arrowhead’s sole and exclusive remedy with respect to any breach of Takeda’s diligence obligations under this Section 7.1.2 (Commercialization Diligence Obligations) will be its right to terminate this Agreement in accordance with Section 15.4 (Termination for Material Breach).
Commercialization Diligence Obligations. As between the Parties, EQRx will be responsible for Commercialization of, and will use [***] to Commercialize, the Licensed Products that contain each Licensed Antibody in each country or region in the Territory in which it has obtained Regulatory Approval (and, where applicable, Pricing and Reimbursement Approval) for such Licensed Products, [***]
Commercialization Diligence Obligations. [*]. If, with respect to any Licensed Program, FibroGen ceases all Commercially Reasonable Efforts to Commercialize all Licensed Products within such Licensed Program for [*], such Licensed Program shall be a Terminated Licensed Program and all applicable Licensed Products shall become Terminated Licensed Products; provided that (a) if such cessation is a result of a safety concern, regulatory issue, clinical hold, Force Majeure, or injunction or other operation of law, such [*] period will be extended for [*] any of the foregoing listed in this clause (a) caused [*] and FibroGen is diligently seeking to remedy such issue, such [*] period will be [*] as is reasonably necessary to resolve the [*]. If FibroGen makes a [*] Commercialization of all Licensed Products for a Licensed Program, FibroGen shall give HFB written notice within [*] of such decision and such Licensed Program shall be a Terminated Licensed Program pursuant to Section 13.6 (Effects of Termination).
Commercialization Diligence Obligations. (a)Following receipt of Marketing Approval for a Product in the Company Field in any country in the Company Territory, Company shall use Commercially Reasonable Efforts to Commercialize such Product in the Company Field in the Company Territory; provided, however, that in no event shall Company be obligated to use Commercially Reasonable Efforts to Commercialize more than one Product in any given country in the Company Territory.
